SHORT REPORT

Large copy number variations in combination with point mutations in the *TYMP* and *SCO2* genes found in two patients with mitochondrial disorders

Alžběta Vondráčková¹, Kateřina Veselá¹, Hana Kratochvílová¹, Vendula Kučerová Vidrová¹, Kamila Vinšová¹, Viktor Stránecký², Tomáš Honzík¹, Hana Hansíková¹, Jiří Zeman¹ and Markéta Tesařová^{*,1}

Mitochondrial disorders are caused by defects in mitochondrial or nuclear DNA. Although the existence of large deletions in mitochondrial DNA (mtDNA) is well known, deletions affecting whole genes are not commonly described in patients with mitochondrial disorders. Based on the results of whole-genome analyses, copy number variations (CNVs) occur frequently in the human genome and may overlap with many genes associated with clinical phenotypes. We report the discovery of two large heterozygous CNVs on 22q13.33 in two patients with mitochondrial disorders. The first patient harboured a novel point mutation c.667G > A (p.D223N) in the *SCO2* gene in combination with a paternally inherited 87-kb deletion. As hypertrophic cardiomyopathy (HCMP) was not documented in the patient, this observation prompted us to compare his clinical features with all 44 reported SCO2 patients in the literature. Surprisingly, the review shows that HCMP was present in only about 50% of the SCO2 patients with non-neonatal onset. In the second patient, who had mitochondrial neurogastrointestinal encephalopathy (MNGIE), a maternally inherited 175-kb deletion and the paternally inherited point mutation c.261G > T (p.E87D) in the *TYMP* gene were identified.

European Journal of Human Genetics (2014) 22, 431–434; doi:10.1038/ejhg.2013.148; published online 10 July 2013

Keywords: CNVs; TYMP; SCO2; mitochondrial disorders; cytochrome c oxidase deficiency

INTRODUCTION

Mutations in mitochondrial DNA (mtDNA) or nuclear genes encoding vital mitochondrial proteins result in a clinically heterogeneous group of mitochondrial disorders, which occur at an incidence of 1 in 5000 neonates.¹ Importantly, the genetic basis of mitochondrial disorders is still unexplained in many patients, despite encouraging advances in genetic research.²

Although the existence of large deletions in mtDNA is well known, deletions affecting the nuclear genes are not commonly described in patients with mitochondrial disorders. A homozygous deletion spanning three genes including *NDUFAF2* was found in a patient with fatal multisystem disorder.³ Leary *et al.*⁴ reported heterozygous *de novo* deletion of the *SCO2* allele in combination with point mutation in a patient with neonatal hypertrophic cardiomyopathy (HCMP). Homozygous or heterozygous deletions of several exons of other OXPHOS-related disease genes were identified by application of targeted array CGH in several patients with mitochondrial diseases.^{5,6}

Structural variants of human DNA at least $\geq 1 \text{ kb}$ in length are called copy number variations (CNVs). According to the latest studies, CNVs are significant genetic factors that may influence the apparent phenotype of every individual.⁷ CNVs can expose sequence variants with an unclear effect in genes of unknown function, change epigenetic factors or alter genomic neighbourhood.^{8–10} These facts together with both the nuclear and mitochondrial genetic

backgrounds^{8,11} may further contribute to the complex clinical phenotype of mitochondrial disorders.

In this study, we report the findings of two large heterozygous CNVs on 22q13.33 in combination with *TYMP* or *SCO2* point mutations in two patients with mitochondrial disorders. Moreover, we discuss the phenotype–genotype correlation of our patients considering recent data regarding the heterogeneity of the human genome.

PATIENTS AND METHODS

Patient 1

The boy was born at term after an uncomplicated delivery as a second child of non-consanguineous parents of Caucasian origin. The birth weight was 3380 g and the length was 50 cm. The postnatal adaptation was uneventful, and until the age of 7.5 months, he developed normally. Thereafter, myoclonic movements on extremities were noted, and severe hypotonic syndrome developed. Failure to thrive, bilateral ptosis, divergent strabismus and ataxia were observed from the age of 9 months, accompanied by the regression of his psychomotor development. At the age of 14 months, the boy was microcephalic, with a head circumference of 44.5 cm (<3rd percentile), weight 7.9 kg (<3rd percentile) and length 79 cm (50th percentile), and his psychomotor development was on the level of a 6–9-month-old infant. Brain MRI revealed delayed myelination. EMG and echocardiography were normal. Neither hepatopathy nor elevation of creatine kinase was noted. Metabolic investigation revealed mild hyperlactaciduria (81 mmol/l creatinine, controls <30) accompanied by increased

npg

¹Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Prague, Czech Republic; ²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic *Correspondence: Dr M Tesařová, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University in Prague and General University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 2 128 08, Czech Republic. Tel: +420 224967099; Fax: +420 224967099; E-mail: marketa.tesarova@lf1.cuni.cz Received 17 December 2012; revised 21 May 2013; accepted 27 May 2013; published online 10 July 2013

urinary excretion of the Krebs-cycle intermediates (fumarate 21 mg/g creatinine, controls <15; aconitate 150 mg/g creatinine, controls <100; 2-oxoglutarate 216 mg/g creatinine, controls <200). Lactate concentration was elevated in CSF (3 mmol/l, controls <2). The patient died due to further deterioration of the disease at the age of 20 months.

Patient 2

The boy was born at term after an uncomplicated delivery as a first child of non-consanguineous parents of Caucasian origin. The birth weight was 3550 g and the length was 52 cm. The postnatal adaptation was uneventful. Severe failure to thrive developed at the age of 4-5 years. At the age of 10 years, his weight was only 16 kg. He had frequent attacks of abdominal pain and alternation of diarrhoea and constipation due to gastrointestinal dysmotility, leading to extreme nausea and intermittent vomiting. X-ray investigation of the gastrointestinal tract found jejunal diverticulosis. Physical endurance was diminished: he was not able to climb stairs and his ability to ride a bicycle was very limited. At the age of 12 years, brain MRI showed white matter abnormalities compatible with the diagnosis of leukodystrophy, and an EMG study revealed polyneuropathy. At the age of 13 years, his weight was 17.5 kg (-4.67 SD), height 135 cm (-3.78 SD) and head circumference 52 cm (3rd percentile). Neurological investigation documented severe hypotonic syndrome, general hyporeflexia and muscle hypotrophy. Psychological investigation showed normal mental capabilities. Retinitis pigmentosa developed at the age of 16 years. At present, the 16-year-old boy is on total parenteral nutrition, and his weight is 24 kg. The severe gastrointestinal dysmotility precludes any enteral feeding. He is wheelchair-bound. He attends school on an intermittent basis. There was neither hepatopathy nor elevation of creatine kinase. During acute gastroenteritis, protein-losing enteropathy developed, leading to hypoalbuminemia (19g/l, controls 35-53) with oedema and ascites. Metabolic investigation revealed mild hyperlactaciduria (81 mmol/l creatinine, controls <30) accompanied by increased urinary excretion of the Krebs-cycle intermediates (fumarate 18 mg/g creatinine, controls < 15; aconitate 140 mg/gcreatinine, controls <100) and 3-methylglutaconic aciduria (45 mg/g creatinine, controls <15). The lactate concentration in blood was not elevated. We found increased levels of uracil (93 mmol/mol creatinine, controls <15), thymine (15.4 mmol/mol creatinine, controls <15), deoxyuridine (39 mmol/ mol creatinine, controls not detectable) and thymidine (12.6 mmol/mol creatinine, controls not detectable).

Molecular genetic analysis

Genomic DNA was extracted from peripheral blood lymphocytes using standard procedures. The nuclear DNA of these patients was analysed using a Genome-Wide Human SNP 6.0 microarray chip (Affymetrix, Santa Clara, CA, USA). The presence of just one copy of the *SCO2* and *TYMP* genes in both affected patients was verified by a real-time PCR CNV assay (Hs00093549_cn, Hs00001601_cn, Hs00137275_cn, Hs00574610_cn; Applied Biosystems, Foster City, CA, USA). Sequencing of coding exons and their flanking intronic regions of *SCO2* (NG_016235.1) and *TYMP* (NG_011860.1) PCR products was performed in both directions on an ABI PRISM 3100/3100-Avant Genetic Analyser (Applied Biosystems). The identified missense mutations were verified by PCR-RFLP analysis, and their impact was evaluated by *in silico* analysis methods using the PolyPhen-2 (http://genetics.bwh.harvard.edu/ pph2), MutPred (http://mutpred.mutdb.org) and SNPs&GO (http://snps-and-go.biocomp.unibo.it/snps-and-go) databases.

Other methods used are described in Supplementary file 1 Methods.

Ethics

This study was approved by the Ethics Committee of the General University Hospital in Prague. All blood and tissue samples were analysed with the informed consent of the parents of the patients.

RESULTS

In patient 1, a paternally inherited 87-kb deletion on Chr. 22: g.[(49275958_49362964)del (NCBI Build 36.1)] spanning eight genes (*LMF2, NCAPH2, SCO2, TYMP, ODF3B, KLHDC7B, c220rf41* and

CPT1B) was identified by microarrays (see Supplementary Figure 1) and confirmed by a real-time PCR CNV assay (see Supplementary Figure 2). This deletion corresponds to a known CNV-variation_4139, which occurs with a frequency of ~0.4% in control samples.¹² In combination with this deletion, a novel point mutation c.667G>A (p.Asp223Asn) in the SCO2 gene was found. The alignment of SCO2 proteins from multiple species showed that the affected Asp223 is completely conserved. The novel missense SCO2 mutation was not present in 100 Czech healthy control samples. No pathogenic mutation was found in the TYMP gene. In muscle and heart mitochondria, a markedly decreased amount of SCO2 protein was found by immunoblot analysis (Figure 1). Lower levels of copper content (Table 1) were detected in autoptic liver (10% of control value), brain, heart and muscle (60-70% of control value), further suggesting cytochrome c oxidase (COX) deficiency due to SCO2 dysfunction¹³ in this patient. In addition, the pathogenicity of this mutation was predicted by in silico analysis with PolyPhen-2, MutPred and SNPs&GO.

In patient 2, a maternally inherited 175-kb deletion on Chr. 22: g.[(49275958_49451008)del (NCBI Build 36.1)] spanning 12 genes (*LMF2, NCAPH2, SCO2, TYMP, ODF3B, KLHDC7B, c22orf41, CPT1B, CHKB, LOC100144603, MAPKIP2* and *ARSA*) along with the paternally inherited point mutation c.261G>T (p.Glu87Asp) in the *TYMP* gene were identified (see Supplementary Figure 1). Although the nucleotide substitution c.261G>T has not been described previously, the resulting amino-acid replacement p.Glu87Asp has already been characterised.¹⁴ The 175-kb deletion spans 12 genes and corresponds to known CNV-variation_5192, which occurs with almost 7% frequency in control samples.¹² In this



Figure 1 Steady-state levels of SCO2 protein in muscle (a) and heart (b) mitochondria of patient 1. A total of $10\,\mu$ g of mitochondrial protein from muscle and heart mitochondria was separated using SDS-PAGE (12% polyacrylamide), electroblotted onto PVDF membranes and detected with polyclonal antiserum raised against human SCO2 or with monoclonal antibody raised against the COX1, COX2 subunits and porin. Two aliquots of control mitochondria corresponding to indicated dilutions of control samples were loaded on the same gels.

Table	1 Total cop	pper content	t in auto	ptic ti	issues o	of patient	1 with
SCO2	deficiency	(expressed	in μ g in	1 g of	f dry tis	sue)	

	С	Copper content (µg/g)			
	Patient 1	Controls			
Muscle	1.12	1.74 ± 0.53 (n = 9)			
Heart	2.2	$2.98 \pm 0.87 \ (n=8)$			
Brain (frontal cortex)	2.26	$3.06 \pm 1.62 \ (n = 6)$			
Liver	4.49	49.03 ± 24.01 (n=10)			

432

Table 2 Biochemical markers assessed in patient 2 with MNGIE

Biochemical markers	Patient 2	Controls
	16.5	< 0.05
Thymidine in urine (mmol/mol of creatinine)	12.6	Not detected
TP activity in lymphocytes (μ mol/mg/h)	0.002	0.41–0.95 (<i>n</i> =14)
Cytochrome c oxidase (COX) activity in lymphocytes (nmol/mg of protein per 1 min)	19	21–43 (<i>n</i> =51)
Citrate synthase (CS) activity in lymphocytes (nmol/mg of protein per 1 min)	75	49–93
COX/CS	0.24	0.31-0.65

Abbreviation: MNGIE, mitochondrial neurogastrointestinal encephalopathy.

patient, the mitochondrial neurogastrointestinal encephalopathy (MNGIE) diagnosis was biochemically confirmed by the diminished thymidine phosphorylase activity in patient lymphocytes. The levels of thymidine in plasma and urine were increased, and the activity of COX and its ratio to citrate synthase (CS) activity in lymphocytes were decreased (Table 2). No pathogenic mutation was found in the *SCO2* gene.

To evaluate the occurrence of CNVs spanning the *SCO2* gene in the Czech population, a real-time PCR CNV assay was carried out in 50 control samples. However, no CNV encompassing *SCO2* was found in the 50 tested Czech control samples (see Supplementary Figure 3).

DISCUSSION

We described two large CNVs on chromosome 22q13.33 that span up to 12 genes found in two patients with mitochondrial disorders. According to the Database of Genomic Variants, only three documented CNVs of ~87–175 kb on chromosome 22q13.33 and overlapping the *TYMP* and *SCO2* genes, including CNV-variation_4139 and CNV-variation_5192 found in the presented patients, have been identified so far with total frequency of 2.2% in control samples.¹² Only 2 out of the 12 genes, apart from *SCO2* and *TYMP*, affected by the deletions are associated with human disease (Supplementary Table 1). Although mutations in both *ARSA* and *CHKB* result in autosomal recessive disorders, their clinical features, neonatal manifestation of cardiomyopathy with increased creatine kinase activity found in *CHKB*-related muscular dystrophy¹⁵ or mental decline specific for juvenile form of metachromatic leukodystrophy, are distinct from symptoms observed in our patients.

In patient 1, we diagnosed SCO2 deficiency based on genetic analyses. With regard to knowledge of the human SCO2 protein structure, the newly identified hemizygous mutation p.D223N is likely to affect the coordination of copper (I) by the two cysteines of the CXXXC conserved motif and by the conserved His224.16 Furthermore, markedly decreased levels of SCO2 protein and border-low copper content found in tissues of patient 1 are in accordance with previously reported findings in SCO2 patients.^{13,17} To date, we have diagnosed the late non-neonatal onset of SCO2 deficiency in eight patients,¹⁸ but ataxia was not noted in any of these or other reported SCO2 patients (Supplementary Table 2). All of the observed symptoms are typical of SCO2 deficiency. Interestingly, based on the review of published cases, HCMP, which is the key finding in SCO2-deficient patients with neonatal onset, is present only in about 50% of the SCO2 patients with non-neonatal presentation (Supplementary Table 2).

With regard to the biochemical and genetic findings, MNGIE was diagnosed in patient 2. The manifested symptoms of patient 2 were similar to those described previously.¹⁹ Whereas no pathogenic mutation was found in the *SCO2* gene of patient 2, we assume that mildly decreased COX activity in his lymphocytes might be a

consequence of point mtDNA-mutation accumulation due to diminished thymidine phosphorylase activity as reported previously in MNGIE patients.²⁰

The number of mitochondrial proteins in mammals has been estimated to be between 1130 and 1500, but pathogenic defects have been found in only a fraction of these proteins.² Additionally, there is no satisfactory explanation for the phenotype–genotype variability in patients suffering from mitochondrial diseases. However, we believe that the use of advanced whole-genome analysis techniques will shed light on the genetic causes of mitochondrial defects, as well as on the regulation of tissue-specific energy demands.^{9,10} Further improvement in our knowledge of mechanisms based on the presence of variable gene dosage, epigenetic modifications, repetitive sequences, noncoding RNAs, *cis*- and *trans*-splicing, diverse penetrance of diseases, the complex effects of the hundreds of loss-of-function variants present in every individual, and general agreement on the classification of particular genetic variants will clarify the phenotypic diversity in humans.^{21,22}

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the patients and their families for participating in the study. We thank T Adam and V Smolka for referring patient 2 to our clinic. This study was supported by the grants GAUK 28410 and SVV266504 from the Charles University in Prague; IGA NT13114/4 from the Internal Grant Agency of the Ministry of Health of the Czech Republic; and by the research projects P24/LF1/3 and UNCE 204011 from the Charles University in Prague.

- Schafer AM, Taylor RW, Turnbull DM, Chinnery PF: The epidemiology of mitochondrial disorders - past, present, future. *Biochim Biophys Acta* 2004; 1659: 115–120.
- 2 Koopman WJ, Willems PH, Smeitink JA: Monogenic mitochondrial disorders. *N Engl J Med* 2012; **366**: 1132–1141.
- 3 Janssen RJ, Distelmaier F, Smeets R *et al*: Contiguous gene deletion of ELOVL7, ERCC8 and NDUFAF2 in a patient with a fatal multisystem disorder. *Hum Mol Genet* 2009; **18**: 3365–3374.
- 4 Leary SC, Mattman A, Wai T et al: A hemizygous SCO2 mutation in an early onset rapidly progressive, fatal cardiomyopathy. Mol Genet Metab 2006; 89: 129–133.
- 5 Compton AG, Troedson C, Wilson M *et al*: Application of oligonucleotide array CGH in the detection of a large intragenic deletion in POLG associated with Alpers Syndrome. *Mitochondrion* 2011; **11**: 104–107.
- 6 Wang J, Zhan H, Li FY, Pursley AN, Schmitt ES, Wong LJ: Targeted array CGH as a valuable molecular diagnostic approach: experience in the diagnosis of mitochondrial and metabolic disorders. *Mol Genet Metab* 2012; **106**: 221–230.
- 7 Scherer SW, Lee C, Birney E et al: Challenges and standards in integrating surveys of structural variation. Nat Genet 2007; 39: S7–S15.
- 8 De S: Somatic mosaicism in healthy human tissues. *Trends Genet* 2011; **27**: 217–223.
- 9 Chinnery PF, Elliott HR, Hudson G, Samuels DC, Relton CL: Epigenetics, epidemiology and mitochondrial DNA diseases. Int J Epidemiol 2012; 41: 177–187.
- 10 De S, Babu MM: Genomic neighbourhood and the regulation of gene expression. *Curr Opin Cell Biol* 2010; **22**: 326–333.

- 11 Pello R, Martin MA, Carelli V *et al*: Mitochondrial DNA background modulates the assembly kinetics of OXPHOS complexes in a cellular model of mitochondrial disease. *Hum Mol Genet* 2008; **17**: 4001–4011.
- 12 lafrate AJ, Feuk L, Rivera MN *et al*: Detection of large-scale variation in the human genome. *Nat Genet* 2004; **36**: 949–951.
- 13 Stiburek L, Vesela K, Hansikova H, Hulkova H, Zeman J: Loss of function of Sco1 and its interaction with cytochrome c oxidase. Am J Physiol Cell Physiol 2009; 296: C1218–C1226.
- 14 Slama A, Lacroix C, Plante-Bordeneuve V et al: Thymidine phosphorylase gene mutations in patients with mitochondrial neurogastrointestinal encephalomyopathy syndrome. Mol Genet Metab 2005; 84: 326–331.
- 15 Nishino I, Kobayashi O, Goto Y et al: A new congenital muscular dystrophy with mitochondrial structural abnormalities. Muscle Nerve 1998; 21: 40–47.
- 16 Banci L, Bertini I, Ciofi-Baffoni S et al: A structural characterization of human SCO2. Structure 2007; 15: 1132–1140.

- 17 Stiburek L, Vesela K, Hansikova H *et al*: Tissue-specific cytochrome c oxidase assembly defects due to mutations in SCO2 and SURF1. *Biochem J* 2005; **392**: 625–632.
- 18 Vesela K, Hansikova H, Magner M, Zeman J: Cytochrome c oxidase deficiency in childhood. *Paediatr Croat* 2009; 53: 122–126.
- 19 Garone C, Tadesse S, Hirano M: Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. *Brain* 2011; **134**: 3326–3332.
- 20 Nishigaki Y, Marti R, Copeland WC, Hirano M: Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 2003; 111: 1913–1921.
- 21 Riggs ER, Church DM, Hanson K et al: Towards an evidence-based process for the clinical interpretation of copy number variation. *Clin Genet* 2012; 81: 403–412.
- 22 Altshuler DM, Gibbs RA, Peltonen L et al: Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52–58.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)

434